High-Throughput Screening (HTS) for Kinase Inhibitors

How are leading Pharma researchers using HTS to identify kinase inhibitors? Protein kinases play crucial roles in biological processes and aberrant kinase activity in human disease including cancer and autoimmune diseases. View an in-depth discussion with leading Pharma researchers who are targeting kinases for the development of new drugs.

Moderator:
James Netterwald, PhD, MT (ASCP)
Senior Editor
Drug Discovery & Development

Panelists:
Kirk McMillan, PhD
Vice President, Lead Discovery
Exelixis, Inc.

Kim Arndt, PhD
Senior Director, Oncology
Wyeth Research

Pirthipal Singh
Associate Principal Scientist; DECS-LG
AstraZeneca

• Protein kinases account for 25% to 30% of all targets screened in the pharmaceutical industry today.  Which targets offer the most potential?
• Fast, reliable, high-throughput screening methods are necessary to determine which potential kinase inhibitors are worthy of further clinical development and which are not.  Which processes work best?
• Screening platforms based on a variety of different technologies are currently available, but all of them have inherent technical challenges that can affect results; this Webcast will discuss some of the challenges.
• This informative Webcast covers this popular research strategy and everything you need to know about the latest discoveries, challenges, and trends in kinase inhibitor research and HTS.

View this free event on demand now!